Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

CD200R/CD200 inhibits osteoclastogenesis: new mechanism of osteoclast control by mesenchymal stem cells in human.

Varin A, Pontikoglou C, Labat E, Deschaseaux F, Sensebé L.

PLoS One. 2013 Aug 5;8(8):e72831. doi: 10.1371/journal.pone.0072831. Print 2013.

2.

Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.

Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, Nakagawa N, Yasuda H, Goto M, Tsuda E, Higashio K, Gillespie MT, Martin TJ, Suda T.

Bone. 1999 Nov;25(5):517-23.

PMID:
10574571
4.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

5.

Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development.

Mori Y, Tsuji S, Inui M, Sakamoto Y, Endo S, Ito Y, Fujimura S, Koga T, Nakamura A, Takayanagi H, Itoi E, Takai T.

J Immunol. 2008 Oct 1;181(7):4742-51.

6.

Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.

Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.

Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45.

PMID:
15752732
7.

CD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells.

Pietilä M, Lehtonen S, Tuovinen E, Lähteenmäki K, Laitinen S, Leskelä HV, Nätynki A, Pesälä J, Nordström K, Lehenkari P.

PLoS One. 2012;7(2):e31671. doi: 10.1371/journal.pone.0031671. Epub 2012 Feb 20.

8.

Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression.

Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaissé JM, Foged NT.

J Biol Chem. 2003 Nov 7;278(45):44975-87. Epub 2003 Aug 20.

9.

Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.

Yonezawa T, Hasegawa S, Asai M, Ninomiya T, Sasaki T, Cha BY, Teruya T, Ozawa H, Yagasaki K, Nagai K, Woo JT.

Eur J Pharmacol. 2011 Jan 15;650(2-3):511-8. doi: 10.1016/j.ejphar.2010.10.048. Epub 2010 Nov 1.

PMID:
21047508
10.

Different Blood-Borne Human Osteoclast Precursors Respond in Distinct Ways to IL-17A.

Sprangers S, Schoenmaker T, Cao Y, Everts V, de Vries TJ.

J Cell Physiol. 2016 Jun;231(6):1249-60. doi: 10.1002/jcp.25220. Epub 2015 Nov 9.

PMID:
26491867
11.

Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.

Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ.

J Bone Miner Res. 2000 Aug;15(8):1459-66.

12.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

13.

Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.

Kim WS, Kim HJ, Lee ZH, Lee Y, Kim HH.

Exp Cell Res. 2013 Feb 15;319(4):436-46. doi: 10.1016/j.yexcr.2012.12.004. Epub 2012 Dec 12.

PMID:
23246654
15.

Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes.

Shinoda K, Sugiyama E, Taki H, Harada S, Mino T, Maruyama M, Kobayashi M.

Bone. 2003 Oct;33(4):711-20.

PMID:
14555277
16.

Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor.

Kaneda T, Nojima T, Nakagawa M, Ogasawara A, Kaneko H, Sato T, Mano H, Kumegawa M, Hakeda Y.

J Immunol. 2000 Oct 15;165(8):4254-63.

17.

Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes.

Najar M, Raicevic G, Jebbawi F, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L.

Immunol Lett. 2012 Aug 30;146(1-2):50-6. doi: 10.1016/j.imlet.2012.04.017. Epub 2012 May 2.

PMID:
22575528
18.

The molecular basis of osteoclast differentiation and activation.

Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N.

Novartis Found Symp. 2001;232:235-47; discussion 247-50. Review.

PMID:
11277084
19.

NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.

Merle B, Itzstein C, Delmas PD, Chenu C.

J Cell Biochem. 2003 Oct 1;90(2):424-36.

PMID:
14505357
20.

TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.

Kanazawa K, Kudo A.

J Bone Miner Res. 2005 May;20(5):840-7. Epub 2004 Dec 20.

Supplemental Content

Support Center